Citations

Mayo Clinic

Clear

1932 citation(s) found for "Nuñez, Jessica".

Genetic effects on sleep/wake variation of seizures
Winawer, Melodie R., Shih, Jerry J. , Hunter, Jessica Ezzell , Epstein, Michael P. , Investigators, the EPGP, Sadleir, Lynette G. , Shih, Jerry, Beck, Erin S , Investigators, the EPGP

Epilepsia | March 7, 2016 | Volume: 57 | Issue: 4 | Pages: 557-565

10.1111/epi.13330 | PMID 26948972 Get It

SummaryObjectiveThere is a complex bidirectional relationship between sleep and epilepsy. Sleep/wake timing of seizures has been investigated for several individual seizure types and syndromes, but few large‐scale studies of the timing of seizures exist in people with varied epilepsy types. In addition, the genetic contributions to seizure timing have not been well studied.MethodsSleep/wake timing of seizures was determined for 1,395 subjects in 546 families enrolled in the Epilepsy Phenome/Genome Project (EPGP). We examined seizure timing among subjects with different epilepsy types, seizure types, epilepsy syndromes, and localization. We also examined the familial aggregation of sleep/wake occurrence of seizures.ResultsSeizures in nonacquired focal epilepsy (NAFE) were more likely to occur during sleep than seizures in generalized epilepsy (GE), for both convulsive (odds ratio [OR] 5.2, 95% confidence interval [CI] 3.59–7.52) and nonconvulsive seizures (OR 4.2, 95% CI 2.48–7.21). Seizures occurring within 1 h of awakening were more likely to occur in patients with GE than with NAFE for both convulsive (OR 2.3, 95% CI 1.54–3.39) and nonconvulsive (OR 1.7, 95% CI 1.04–2.66) seizures. Frontal onset seizures were more likely than temporal onset seizures to occur during sleep. Sleep/wake timing of seizures in first‐degree relatives predicted timing of seizures in the proband.SignificanceWe found that sleep/wake timing of seizures is associated with both epilepsy syndrome and seizure type. In addition, we provide the first evidence for a genetic contribution to sleep/wake timing of seizures in a large group of individuals with common epilepsy syndromes.
Validating endpoints for therapeutic trials in fecal incontinence
Noelting, Jessica , Zinsmeister, Alan R., Bharucha, Adil E.

Neurogastroenterology & Motility | March 7, 2016 | Volume: 28 | Issue: 8 | Pages: 1148-1156

10.1111/nmo.12809 | PMID 26948292 Get It

AbstractBackgroundA 50% or greater reduction in the frequency of fecal incontinence (FI) recorded with daily bowel diaries is the primary endpoint in clinical trials of FI. Whether this difference is clinically important is unknown. The relationship between FI symptoms recorded with daily and weekly instruments is unknown. The contribution of psychological factors to quality of life (QOL) in FI is unclear.MethodsFecal incontinence severity was assessed with daily bowel diaries and periodic questionnaires (fecal incontinence severity score [FISS], FIQOL, 36‐Item Short Form Health Survey [SF‐36], and hospital anxiety and depression scales) for 4 weeks before and during double‐blind randomization to placebo or clonidine in 44 women with FI. The reduction in FI frequency was compared to the minimal clinically important difference (MCID) computed from the FISS. Endpoints of FI were compared between daily and weekly diaries.Key ResultsThe FISS exceeded the MCID in 75% and 83% of patients in whom the FI frequency declined by 50–74% and ≥75% respectively. Parameters of FI measured with daily and weekly instruments were significantly correlated. The daily parameters explained 71% of the inter‐patient variation in the FISS. The SF‐36 health scores, rather than the FISS rating, explained a majority of the inter‐subject variation in FIQOL.Conclusions & InferencesMost patients who report a ≥50% reduction in FI frequency experience a clinically important improvement. Weekly questionnaires accurately assess the severity of FI. Self‐reported physical and mental health explained a greater proportion of the variance in FIQOL than FI symptom severity.
APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations
Shinohara, Mitsuru , Kanekiyo, Takahisa , Yang, Longyu, Linthicum, Duane, Shinohara, Motoko, Fu, Yuan , Frisch‐Daiello, Jessica L., Fryer, John Denis , Bu, Guojun , Price, Laura, Fryer, John D., Price, Laura, Han, Xianlin , Bu, Guojun

Annals of Neurology | March 2, 2016 | Volume: 79 | Issue: 5 | Pages: 758-774

10.1002/ana.24628 | PMID 26933942 Get It

ObjectiveApolipoprotein E (apoE), a major cholesterol carrier in the brain, is associated with a strong risk for Alzheimer disease. Compared to the risky APOE4 gene allele, the effects of the protective APOE2 gene allele are vastly understudied, and thus need to be further clarified.MethodsWe reviewed National Alzheimer's Coordinating Center clinical records and performed preclinical experiments using human apoE‐targeted replacement (apoE‐TR) mice, which do not show amyloid pathology.ResultsClinically, the APOE2 allele was associated with less cognitive decline during aging. This effect was also seen in subjects with little amyloid pathology, or after adjusting for Alzheimer disease‐related pathologies. In animal studies, aged apoE2‐TR mice also exhibited preserved memory function in water maze tests. Regardless, apoE2‐TR mice showed similar or greater age‐related changes in synaptic loss, neuroinflammation, and oxidative stress compared to apoE3‐TR or apoE4‐TR mice. Interestingly, apoE concentrations in the cortex, hippocampus, plasma, and cerebrospinal fluid (CSF) were positively correlated with memory performance across apoE isoforms, where apoE2‐TR mice had higher apoE levels. Moreover, apoE2‐TR mice exhibited the lowest levels of cholesterol in the cortex, despite higher levels in CSF and plasma. These cholesterol levels were associated with apoE levels and memory performance across apoE isoforms.InterpretationAPOE2 is associated with less cognitive decline during aging. This can occur independently of age‐related synaptic/neuroinflammatory changes and amyloid accumulation. Higher levels of apoE and associated cholesterol metabolism in APOE2 carriers might contribute to this protective effect. Ann Neurol 2016;79:758–774
Further Defining the Role of the Laboratory Genetic Counselor
Waltman, Lindsey, Runke, Cassandra , Balcom, Jessica R. , Riley, Jacquelyn D. , Lilley, Margaret , Christian, Susan , Zetzsche, Lindsay H., Goodenberger, McKinsey L. , Balcom, Jessica, Zetzsche, Lindsay, Goodenberger, McKinsey

Journal of Genetic Counseling | February 20, 2016 | Volume: 25 | Issue: 4 | Pages: 786-798

10.1007/s10897-015-9927-4 | PMID 26895873 Get It

AbstractLaboratory genetic counseling is becoming increasingly common as a result of increased laboratory services and genetic testing menus, as well as growing job responsibilities. Christian et al. (2012) provided the first quantitative data regarding the roles of the laboratory‐based genetic counselor (LBGC) finding that two of the most prevalent roles are as customer liaisons and communicators of test results. The goal of the present study was to further delineate the role of the LBGC by addressing specific tasks that LBGCs are involved with on a day‐to‐day basis. A survey was designed to expand upon themes identified in the Christian et al. (2012) study by querying specific tasks performed in several categories of potential LBGC job duties. An invitation for LBGCs to participate was distributed via email to the membership of the National Society of Genetic Counselors (NSGC) and the Canadian Association of Genetic Counsellors (CAGC). We identified 121 genetic counselors who primarily work in the laboratory setting or whose job role includes a laboratory component. Almost all respondents performed customer liaison/case coordination (95 %), and interpretation and result reporting (88 %). The most frequently performed tasks within these categories involved addressing questions from clients, making phone calls with genetic testing results, obtaining clinical or family history information for results interpretation, and composing case‐specific interpretations for unique results and/or obtaining literature references to support interpretations. The study results also point to trends of expanding roles in sales and marketing, variant interpretation and management responsibilities. Results of this study may be useful to further define the full scope of practice of LBGCs, aid in the development of new LBGC positions and expand current positions to include roles related to test development, research, and student supervision. It may also aid in curriculum updates for training programs to increase exposure to LBGC roles.
Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum
Flanagan, Eoin P. , Cabre, Philippe, Weinshenker, Brian G. , Sauver, Jennifer L. St. , Jacobson, Debra J., Majed, Masoud , Lennon, Vanda A. , Lucchinetti, Claudia F. , McKeon, Andrew , Matiello, Marcelo , Kale, Nilifur, Wingerchuk, Dean M. , Mandrekar, Jay , Sagen, Jessica, Fryer, James P., Robinson, Angala Borders, Pittock, Sean J. , Sagen, Jessica A., Pittock, S J , Flanagan, E P , Weinshenker, Brian G , St Sauver, Jennifer L , McKeon, Andrew

Annals of Neurology | February 18, 2016 | Volume: 79 | Issue: 5 | Pages: 775-783

10.1002/ana.24617 | PMID 26891082 Get It

ObjectiveNeuromyelitis optica (NMO) and its spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDDs) with a specific biomarker, aquaporin‐4–immunoglobulin G (AQP4‐IgG). Prior NMO/NMOSD epidemiological studies have been limited by lack of AQP4‐IgG seroprevalence assessment, absence of population‐based USA studies, and under‐representation of blacks. To overcome these limitations, we sought to compare NMO/NMOSD seroepidemiology across 2 ethnically divergent populations.MethodsWe performed a population‐based comparative study of the incidence (2003–2011) and prevalence (on December 31, 2011) of NMO/NMOSD and AQP4‐IgG seroincidence and seroprevalence (sera collected in 80–84% of IDD cases) among patients with IDD diagnosis in Olmsted County, Minnesota (82% white [Caucasian]) and Martinique (90% black [Afro‐Caribbean]). AQP4‐IgG was measured by M1 isoform fluorescence‐activated cell‐sorting assays.ResultsThe age‐ and sex‐adjusted incidence (7.3 vs 0.7/1,000,000 person‐years [p < 0.01]) and prevalence (10 vs 3.9/100,000 [p = 0.01]) in Martinique exceeded that in Olmsted County. The AQP4‐IgG age‐ and sex‐adjusted seroincidence (6.5 vs 0.7/1,000,000 person‐years [p < 0.01]) and seroprevalence (7.9 vs 3.3/100,000 [p = 0.04]) were also higher in Martinique than Olmsted County. The ethnicity‐specific prevalence was similar in Martinique and Olmsted County: 11.5 and 13/100,000 in blacks, and 6.1 and 4.0/100,000 in whites, respectively. NMO/NMOSD represented a higher proportion of IDD cases in Martinique than Olmsted County (16% vs 1.4%; p < 0.01). The onset age (median = 35–37 years) and female:male distribution (5–9:1) were similar across both populations; 60% of prevalent cases were either blind in 1 eye, dependent on a gait aid, or both.InterpretationThis study reports the highest prevalence of NMO/NMOSD in any population (10/100,000 in Martinique), estimates it affects 16,000 to 17,000 in the USA (higher than previous predictions), and demonstrates it disproportionately affects blacks. Ann Neurol 2016;79:775–783
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
Dorsey, E. Ray , Achey, Meredith A. , Beck, Christopher A. , Beran, Denise B., Biglan, Kevin , Boyd, Cynthia M. , Schmidt, Péter , Simone, Richard, Willis, Allison W. , Galifianakis, Nicholas B. , Katz, Maya , Dodenhoff, Kristen A. , Ziman, Nathan, Aldred, Jason , Carter, Julie, Jimenez‐Shahed, Joohi , Hunter, Christine , Spindler, Meredith , Morgan, John C. , McLane, Dedi, Hickey, Patrick , Gauger, Lisa, Richard, Irene Hegeman, Bull, Michael, Mejia, Nicte I. , Bwala, Grace, Nance, Martha , Shih, Ludy C. , Anderson, Lauren , Singer, Carlos , Zadikoff, Cindy , Okon, Natalia, Feigin, Andrew, Ayan, J., Vaughan, Christina , Cooper, Jessica , Webb, S. J., Dhall, Rohit , Hassan, Anhar , Weis, Delana, DeMello, Steven, Smith, Joseph M. , Keenan, H. Tait, Korn, Ryan, Schwarz, Heidi B., Stevenson, E. Anna , Zhu, William , Tanner, Caroline M. , Mari, Zoltan K. , Pahwa, Rajesh , Riggare, Sara S. , Wicks, Paul J , Sharma, Saloni , Jimenez-Shahed, Joohi

Telemedicine and e-Health | February 17, 2016 | Volume: 22 | Issue: 7 | Pages: 590-598

10.1089/tmj.2015.0191 | PMID 26886406 Get It

Background: Delivering specialty care remotely directly into people's homes can enhance access for and improve the healthcare of individuals with chronic conditions. However, evidence supporting this approach is limited. Materials and Methods: Connect.Parkinson is a randomized comparative effectiveness study that compares usual care of individuals with Parkinson's disease in the community with usual care augmented by virtual house calls with a Parkinson's disease specialist from 1 of 18 centers nationally. Individuals in the intervention arm receive four virtual visits from a Parkinson's disease specialist over 1 year via secure, Web-based videoconferencing directly into their homes. All study activities, including recruitment, enrollment, and assessments, are conducted remotely. Here we report on interest, feasibility, and barriers to enrollment in this ongoing study. Results: During recruitment, 11,734 individuals visited the study's Web site, and 927 unique individuals submitted electronic interest forms. Two hundred ten individuals from 18 states enrolled in the study from March 2014 to June 2015, and 195 were randomized. Most participants were white (96%) and college educated (73%). Of the randomized participants, 73% had seen a Parkinson's disease specialist within the previous year. Conclusions: Among individuals with Parkinson's disease, national interest in receiving remote specialty care directly into the home is high. Remote enrollment in this care model is feasible but is likely affected by differential access to the Internet.
Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings
Dugger, Brittany N. , Hentz, Joseph G. , Hinni, Michael L., Driver‐Dunckley, Erika , Mehta, Shyamal, Sue, Lucia I., Duffy, Amy, Intorcia, Anthony J., Filon, Jessica, Pullen, Joel, Walker, Douglas G. , Beach, Thomas G. , Driver-Dunckley, Erika, Adler, Charles H. , Lott, David G. , Mehta, Shyamal H. , Serrano, Geidy E. , Dugger, Brittany N

Movement Disorders | January 22, 2016 | Volume: 31 | Issue: 2 | Pages: 250-256

10.1002/mds.26476 | PMID 26799362 Get It

ABSTRACTIntroductionFinding a peripheral tissue biopsy site to diagnose early PD would be of value for clinical care, biomarker validation, and as research enrollment criteria. Whereas autopsy and advanced PD studies suggest that the submandibular gland is an important biopsy site, there are no studies in early PD. The aim of this study was to determine whether needle biopsy of the submandibular gland reveals Lewy type alpha‐synucleinopathy in early PD.MethodsTwenty‐five early PD (duration < 5 years) and 10 controls underwent transcutaneous needle core biopsies of the submandibular gland. Tissue was stained for phosphorylated alpha‐synuclein, reviewed blind to clinical diagnosis, and only nerve element staining was considered positive.ResultsMean (standard deviation) age was 69.5 (8.3) for the PD group, 64.8 (8.0) years for controls, and disease duration 2.6 (1.1) years. Six PD and 1 control subject had inadequate glandular tissue. Positive staining was found in 14 of 19 (74%) PD and 2 of 9 (22%) control subjects. PD‐positive and ‐negative cases did not differ clinically. Adverse events (mainly swelling and bruising) were common (77% of cases), but were minor and transient.ConclusionsSubmandibular gland needle biopsies identified phosphorylated alpha‐synuclein staining in 74% of early PD subjects. False positives may be true false positives or may represent prodromal PD. If confirmed in larger studies with eventual autopsy confirmation, the potential value of submandibular gland biopsies for early PD may be to aid in clinical trial inclusion/exclusion and eventually serve as a gold standard for biomarker studies short of autopsy confirmation. © 2016 International Parkinson and Movement Disorder Society
Adolescent Presents With Altered Mental Status and Elevated Anion Gap After Suicide Attempt by Ethylene Glycol Ingestion
Schoen, Jessica C. , Cain, Meghan, Robinson, Jeffrey A. , Schiltz, Brenda , Mannenbach, Mark S.

Pediatric Emergency Care | January 19, 2016 | Volume: 32 | Issue: 10 | Pages: 688-690

10.1097/pec.0000000000000606 | PMID 26785093 Get It

Abstract We report the case of a 16-year-old healthy adolescent male who presented to the local emergency department with altered mental status. En route to a tertiary care facility, he began to decompensate and was found to be markedly acidotic. Further investigation revealed an elevated anion gap, and physical examination showed only abdominal pain and decreased level of consciousness. A broad differential diagnosis was considered at the time of the patient's presentation at the tertiary care center including ingestion of a volatile alcohol, sepsis, and an abdominal catastrophe. Although fomepizole and emergent dialysis were being initiated, laboratory tests confirmed ethylene glycol poisoning. This case demonstrates the importance of early recognition of potential ingestions in patients with altered mental status and supportive laboratory findings.
F3‐03‐04: The Alzheimer's prevention initiative: Genetic testing, disclosure, and counseling strategies
Karlawish, Jason , Bradbury, Angela R. , Patrick‐Miller, Linda , Blacker, Deborah , Caselli, Richard J. , Zallen, Doris T. , Marchant, Gary E. , Langlois, Carolyn, Reiman, Eric M. , Tariot, Pierre N. , Langbaum, Jessica B. S. , Roberts, J. Scott , Wood, Elisabeth McCarty , Kim, Scott Y. H.

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2015.07.233 Get It

P1‐319: Alzheimer's prevention registry: A shared resource to the scientific community to facilitate enrollment in studies
High, Nellie, Reiman, Eric M. , Aisen, Paul, Albert, Marilyn S. , Comer, Meryl, Petersen, Ronald , Strobel, Gabrielle, Weiner, Michael W. , Tariot, Pierre N. , Langbaum, Jessica B. S. , Cummings, Jeffrey L. , Manly, Jennifer J. , Sperling, Reisa Anne

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2015.06.534 Get It